Insmed receives priority medicines (prime) designation from european medicines agency (ema) for brensocatib in patients with non-cystic fibrosis bronchiectasis (ncfbe)

Bridgewater, n.j., nov. 13, 2020 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the european medicines agency (ema) has granted priority medicines...
INSM Ratings Summary
INSM Quant Ranking